# LiRIS Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liris-biomedical

- Industry: Pharmaceuticals
- Headquarters: Lexington, US
- Website: www.tarisbiomedical.com
- Total disclosed funding: $103M
- Latest round: Series B (Dec 21, 2017)
- Investors on record: 8

## About

LiRIS Biomedical, Inc. is a biotechnology firm focused on developing innovative treatments for patients with cancer and other serious diseases. The company leverages advanced technology to enhance therapeutic efficacy and improve patient outcomes.LiRIS Biomedical, Inc. specializes in the development of targeted therapeutic solutions for oncology. Founded in 2008 in Lexington, US, the company has successfully completed a total of 9 deals, with its most recent deal occurring on December 20, 2019. On this date, LiRIS Biomedical was acquired by Johnson & Johnson, although financial terms were not disclosed. The company was founded by a team of professionals with expertise in biomedical engineering and drug development, although individual founder names are not mentioned. The latest funding round was a Series B, which raised USD 25.00 mn led by Yonghua Capital, with participation from Bristol-Myers Squibb Company, Flagship Pioneering, Norma Investment, Polaris Partners, and RA Capital, resulting in a total amount raised of USD 25.00 mn.LiRIS Biomedical, Inc. provides advanced biotechnological solutions primarily in the field of cancer treatment. The company's product offerings are centered around targeted therapies aimed at addressing specific cancer types, enhancing treatment precision and efficiency. Their focus on innovation is evident in the ongoing development of therapies that aim to meet the needs of healthcare providers and patients alike.LiRIS Biomedical, Inc. generates revenue through the commercialization of its innovative therapeutic products. The revenue model is based on B2B transactions with healthcare institutions and potential partnerships with pharmaceutical distributors and healthcare providers. The company's pricing strategy reflects the advanced nature of its products, ensuring competitive positioning within the oncology market.LiRIS Biomedical, Inc. plans to utilize the funds from the Series B round to accelerate the development of new therapeutic products targeting various cancers. The company is also looking to expand its market reach into Europe and Asia by 2022, aiming to establish partnerships with healthcare providers in these regions. Following the acquisition by Johnson & Johnson, the company will leverage additional resources to enhance its research capabilities and foster innovation in cancer treatments.

## Funding rounds

- Series B, Dec 21, 2017, $25M — Flagship Pioneering, Polaris Partners, Bristol-Myers Squibb Company, Yonghua Capital, RA Capital Management, Norma Investment
- Series A, Oct 27, 2015, $32M — Flagship Pioneering, Polaris Partners, RA Capital Management
- Series B, Mar 19, 2013, $13M — Flagship Pioneering, Polaris Partners, Third Rock Ventures, Flybridge Capital Partners
- Series B, Apr 6, 2011, $18M — Flagship Pioneering, Polaris Partners, Third Rock Ventures, Flybridge Capital Partners
- Series A, Jun 25, 2009, $15M — Flagship Pioneering, Polaris Partners, Flybridge Capital Partners

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Flybridge Capital Partners (https://capitalatlas.ai/funds/flybridge-capital-partners) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Bristol-Myers Squibb Company — Series B
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series B
- Norma Investment — Series B